TY - JOUR
T1 - One step closer to influenza vaccine inclusiveness
AU - Sgrulletti, Mayla
AU - Ottaviano, Giorgio
AU - Sangerardi, Maria
AU - Chini, Loredana
AU - Dellepiane, Rosa Maria
AU - Martire, Baldassarre
AU - Montin, Davide
AU - Rizzo, Caterina
AU - Moschese, Viviana
N1 - Publisher Copyright:
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Flu virus infection is a common cause of acute respiratory illness, with the major incidence in pediatric age, high morbidity, and mortality. The flu vaccine is recommended for all people aged ≥6 months, unless specific contraindications are present. Younger and older age, pregnancy, chronic diseases like asthma, and immunodeficiency are risk factors for severe complications following flu infection. Thus, these categories represent the target for flu vaccine strategies in most countries. Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) or live-attenuated influenza virus (LAIV) are currently available, with specific precautions and contraindications. We aim to resume the current indications for vaccines in the vulnerable populations to support flu vaccination inclusiveness, in anticipation of a “universal vaccine” strategy.
AB - Flu virus infection is a common cause of acute respiratory illness, with the major incidence in pediatric age, high morbidity, and mortality. The flu vaccine is recommended for all people aged ≥6 months, unless specific contraindications are present. Younger and older age, pregnancy, chronic diseases like asthma, and immunodeficiency are risk factors for severe complications following flu infection. Thus, these categories represent the target for flu vaccine strategies in most countries. Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) or live-attenuated influenza virus (LAIV) are currently available, with specific precautions and contraindications. We aim to resume the current indications for vaccines in the vulnerable populations to support flu vaccination inclusiveness, in anticipation of a “universal vaccine” strategy.
KW - asthma
KW - children
KW - immunodeficiency
KW - influenza vaccine
KW - pregnancy
KW - universal vaccine
UR - http://www.scopus.com/inward/record.url?scp=85096432301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096432301&partnerID=8YFLogxK
U2 - 10.1111/pai.13338
DO - 10.1111/pai.13338
M3 - Article
C2 - 33236432
AN - SCOPUS:85096432301
VL - 31
SP - 69
EP - 71
JO - Pediatric Allergy and Immunology
JF - Pediatric Allergy and Immunology
SN - 0905-6157
IS - S26
ER -